Delve Bio

Executive Summary

Delve Bio is a San Francisco-based diagnostics company pioneering metagenomic next-generation sequencing (mNGS) for infectious disease diagnosis. Its flagship test, Delve Detect, targets central nervous system (CNS) infections such as meningitis and encephalitis, enabling comprehensive pathogen detection from a single cerebrospinal fluid (CSF) sample. As an exclusive licensee of UCSF's mNGS technology, the company combines cutting-edge genomic analysis with expert clinical interpretation to address the critical diagnostic gap in CNS infections, where rapid and accurate etiology identification can significantly improve patient outcomes. Delve Bio's approach aims to reduce the reliance on conventional, time-consuming methods and provide a more holistic view of the microbial landscape in the CNS, potentially transforming the standard of care for these serious conditions.

Upcoming Catalysts (preview)

• H2 2026FDA Clearance or Breakthrough Device Designation for Delve Detect65% success
• Q3 2026Publication of Pivotal Clinical Validation Study Results70% success
• Q4 2026Announcement of Strategic Commercial Partnership60% success